Overall Status

Recruiting (2)

Unknown status (1)

Phase

early phase 1 (1)

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Institut Paoli-Calmettes (1)

Medical College of Wisconsin (1)

University of Birmingham (1)

Collaborator

AstraZeneca (1)

Cancer Research UK (1)

Children's Hospital and Health System Foundation, Wisconsin (1)

INATHERYS (1)

Intervention

car-20/19-t cells (1)

car-20/19-t cells (1 x 10^5 car-20/19-t cells/kg) (1)

car-20/19-t cells (2.5 x10^5 car-20/19-t cells/kg) (1)

car-20/19-t cells (2.5 x10^6 car-20/19-t cells/kg) (1)

car-20/19-t cells (7.5 x10^5 car-20/19-t cells/kg) (1)

dexamethasone (1)

ina03 administration (1)

selumetinib (1)

Study Documents

Intervention Type

drug (2)

biological (1)

Funder Type

Other (3)

Study Type

Interventional (3)

acute lymphoblastic leukemia recurrent

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting

Acute Lymphoblastic Leukemia, in Relapse
+5 more

CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
+4 more

Milwaukee, Wisconsin

Medical College of Wisconsin

Sep 22, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,

Recruiting

Acute Lymphoblastic Leukemia
+4 more

Copenhagen, Denmark
+16 more

Jan 26, 2022

Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse Trial in

Unknown status

Acute Lymphoblastic Leukemia Recurrent
+4 more

INA03 administration

Marseille, Bouches-du Rhône, France
+1 more

Feb 4, 2020